1-4 of 4
Matt Rosales
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Clinical Trials & Observations
Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K Singh, Mark R Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander E. Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K. Waller, Sumithira Vasu, Melhem M Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty J Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Caroline Chen, Nahla Hasabou, Matt Rosales, Jason E. Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Adam M Mendizabal, Steven M. Devine, Mary M Horowitz, Yi-Bin Chen
Journal: Blood
Blood blood.2024025154.
https://doi.org/10.1182/blood.2024025154
Published: 2025
Includes: Supplemental data
Journal Articles

BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3- ITD + AML

Mark J. Levis, MD, Mehdi Hamadani, MD, Brent R. Logan, Matt Rosales, David Delgado, Erkut Bahceci, Steven Devine, MD, Mary M. Horowitz, Yi-Bin Chen
Journal: Blood
Blood (2019) 134 (Supplement_1): 4602.
https://doi.org/10.1182/blood-2019-124322
Published: 2019
Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood
Blood (2019) 134 (Supplement_1): 14.
https://doi.org/10.1182/blood-2019-122620
Published: 2019
Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1458.
https://doi.org/10.1182/blood-2018-99-110971
Published: 2018